Canadians may be eligible for a piece of this class-action involving a drug used to treat depression, schizophrenia
Canadians can claim part of a $4.75 million Rexulti settlement for compulsive‑behaviour side effects, with a deadline of Aug. 27.Summary
The Quebec Superior Court approved a $4.75 million settlement in November 2025 for a national class action against Otsuka Canada Pharmaceutical Inc. and Lundbeck Canada Inc. over the antipsychotic drug Rexulti (brexpiprazole). The class includes Canadians who were prescribed Rexulti since February 2017 and later developed compulsive behaviours or impulse‑control disorders such as gambling, shopping or binge‑eating. Claimants have until August 27, 2026 to file for a share of the settlement, with potential payouts ranging from about $6,500 for mild cases to over $102,000 for severe cases. Lawyers note the settlement is a compromise with no admission of liability. The notice was first published by The Canadian Press on July 27, 2026.
(Source：CP24 Toronto)